A prospective phase III validation study found that AZGP1 has significant prognostic utility as a biomarker in localized prostate cancer.
The FDA granted accelerated approval to rucaparib (Rubraca), a PARP inhibitor, for the treatment of women with deleterious BRCA mutation-associated ovarian cancer.
The addition of selumetinib to docetaxel failed to improve progression-free and overall survival in patients with KRAS-mutated locally advanced or metastatic NSCLC.
Adding ribociclib, a CDK4/6 inhibitor, to letrozole significantly improved progression-free survival in postmenopausal women with advanced, HR-positive/HER2-negative breast cancer.
The FGFR inhibitor dovitinib showed modest efficacy in a phase II trial of patients with pretreated, advanced squamous cell lung cancer with FGFR1 amplification
First-line crizotinib therapy offered better intracranial disease control rate than chemotherapy in patients with ALK-positive non–small-cell lung cancer (NSCLC) and stable treated brain metastases.
An integrated genomic analysis has found that pancreatic cancer can be divided into four specific subtypes based on molecular characteristics. This division could help guide treatment decisions and future research avenues into this difficult malignancy.
High expression levels of EGFR ligands epiregulin and amphiregulin are associated with increased benefit from panitumumab in patients with RAS wildtype advanced colorectal cancer.
Laboratory studies of mice and human cells found that a protein called Metastasis suppressor 1 (Mtss1) is downregulated in hematopoietic and progenitor cells when chronic myeloid leukemia is present. Mtss1 levels are restored when complete remission is achieved, suggesting the pathway might represent a new therapeutic target.
A laboratory study found that the Hhex protein is overexpressed in acute myeloid leukemia cells and is necessary for their propagation but not for normal myelopoiesis.